---
title: Study on the Myocardial Protective Effect of Upper Limb Ischemic Preconditioning in Patients Undergoing Off-pump Coronary Artery Bypass Grafting
nct_id: NCT03340181
overall_status: UNKNOWN
phase: NA
sponsor: Shanghai Zhongshan Hospital
study_type: INTERVENTIONAL
primary_condition: OPCABG
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03340181.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03340181"
ct_last_update_post_date: 2017-11-13
last_seen_at: "2026-05-12T06:30:00.514Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study on the Myocardial Protective Effect of Upper Limb Ischemic Preconditioning in Patients Undergoing Off-pump Coronary Artery Bypass Grafting

**Official Title:** Study on the Myocardial Protective Effect of RIPC in Patients Undergoing OPCABG

**NCT ID:** [NCT03340181](https://clinicaltrials.gov/study/NCT03340181)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 66
- **Lead Sponsor:** Shanghai Zhongshan Hospital
- **Conditions:** OPCABG
- **Start Date:** 2017-11-01
- **Completion Date:** 2019-06-30
- **CT.gov Last Update:** 2017-11-13

## Brief Summary

The purpose of the study was to verify the myocardial protective effect of RIPC in patients undergoing OPCABG.

## Detailed Description

66 patients scheduled for OPCABG are randomly assigned to a RIPC group(n=33) or a control group(n=33). In the RIPC group, 4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision. Patients in the control group wear the same cuff on an upper limb but no pressure is applied. Anesthetic and surgical techniques are standardized during the trial. Serum inflammatory cytokines and cardiac injury markers will be measured before and after surgery. Internal mammary artery and saphenous vein tissues will be collected during the surgery to assess hypoxia-inducible factor (Hif)-1a and other signalling proteins.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* serious changes in several coronary arteries that need to receive OPCABG
* NHYA II-III
* ASA II-III

Exclusion Criteria:

* LVEF\< 35%
* acute myocardial infarction
* multiple organ dysfunction
```

## Arms

- **RIPC** (EXPERIMENTAL) — 4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
- **control** (SHAM_COMPARATOR) — patient in control group using a blood pressure cuff on an upper limb without inflating

## Interventions

- **RIPC** (OTHER) — 4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.

## Primary Outcomes

- **ICU staying time** _(time frame: average of 1 year)_ — the time patients spend in ICU after surgery

## Locations (1)

- Huilin Wang, Shanghai, Shanghai Municipality, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.huilin wang|shanghai|shanghai municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03340181.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03340181*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*